Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories

02:18 EDT 23rd July 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 1–25 of 6,400+

Relevant

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.


Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12.39. The stock Read more...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases Read more...


Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.84%.

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures,...Read More... The post Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics appeared first on Drug Development Technology.

Alexion to Acquire Wilson Therapeutics and its Rare Liver Disorder Drug

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. Wilson Therapeutics is a biopharmaceutical com...

UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders

LOUVAIN-LA-NEUVE, Belgium, February 8, 2018 /PRNewswire/ -- Syndesi Therapeutics to leverage UCB's expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders wi...

Gain Therapeutics hopes 'pharmacological chaperones' can usher in new therapies for rare diseases

A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered…

Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients With Schizophrenia, MS

NewsNovartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients.

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal

Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Abeona Therapeutics Inc: Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des 4. Quartals 2017 bekannt

Telefonkonferenz für Anleger am Dienstag, 27. März um 10.00 Uhr ET NEW YORK und CLEVELAND (USA), 19. März 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der kli...

Spark Therapeutics, Inc.: Spark Therapeutics nimmt im März an mehreren Konferenzen teil

PHILADELPHIA, 23. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das sich der Herausforderung in Bezug auf die Unvermeidbarkeit g...

Seattle Genetics Acquires Cascadian Therapeutics, Continuing a Strong ...

On January 31, two Seattle biotech companies, Seattle Genetics and Cascadian Therapeutics, announced a merger agreement under which Seattle Genetics will acquire Cascadian Therapeutics for $614 million. [1] The announcement catapulted Cascadian Therapeutics shares to a 16-month high, and a 69% increase over the previous day's closing price.

Spark Therapeutics, Inc.: Spark Therapeutics nimmt an mehreren Konferenzen im Februar teil

PHILADELPHIA, 2018-02-06 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das sich der Herausforderung in Bezug auf die Unvermeidbarkeit genetis...

Abeona Therapeutics Inc: Abeona Therapeutics kündigt bevorstehende Präsentationen auf dem 14. jährlichen WORLDSymposium an

NEW YORK und CLEVELAND (USA), 3. Februar 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der klinischen Erprobung tätiges Biopharmazieunternehmen, das sich auf d...

Novelion Therapeutics Inc.: Novelion Therapeutics Supports World Lipodystrophy Day

VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals ...

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million Read more...

e-Therapeutics and C4XD research Parkinson's drugs

UK biotech e-Therapeutics is to work with genomics firm C4X Discovery to develop new therapies for Parkinson’s disease. e-Therapeutics has been under the leadership of CEO Ray Barlow for more than a year, who has been refocusing the biotech’s rese...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks